Tumor markers in pleural effusions

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1921-1924

  Topolcan, Ondrej ^a,b   Holubec, L ^a   Polivkova, V ^a   Svobodova, S ^a   Pesek, M ^a   Treska, V ^a   Safranek, J ^a   Hajek, T ^a   Bartunek, L ^a   Rousarova, M ^a   Finek, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b First Medical Faculty Prague ^*  (Czech Republic)

Author keywords

Differential diagnosis; Pleural effusions; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; PROCALCITONIN; THYMIDINE KINASE; TISSUE POLYPEPTIDE ANTIGEN; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; BREAST CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PLEURA EFFUSION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CA-15-3 ANTIGEN; CA-19-9 ANTIGEN; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; KERATINS; MALE; MIDDLE AGED; NEOPLASMS; PEPTIDES; PHOSPHOPYRUVATE HYDRATASE; PLEURAL EFFUSION; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; THYMIDINE KINASE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 34250753210     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Porcel JM and Light RW: Diagnostic approach to pleural effusion in adults. Am Fam Physician 73(7): 1211-1220, 2006.
2. Terracciano D, Di Carlo A, Papa P, Cicalese M, Maietta P, Cecere C, Mariano A and Macchia V: New approaches in the diagnostic procedure of malignant pleural effusions. Oncol Rep 12(1): 79-83, 2004.
3. Gulyas M, Elek G, Molnar M and Szollar L: Oncologic diagnosis of serous effusions in body cavities (cytologic study and evaluation of cholesterol and carcinoembryonic antigen levels) Orv Hetil 136(45): 2453-2458, 1995.
4. Nusair S, Breuer R, Amir G and Berkman N: Closed pleural needle biopsy: predicting diagnostic yield by examining pleural fluid parameters. Respir Med 96(11): 890-894, 2002.
5. Puzman P, Terl M and Mukensnabl P: Medical videothoracoscopy in diagnosis and therapy of pleural effusions Vnitr Lek 52(4): 321-327, 2006.
6. Breborowicz D, Majewski P, Simon I, Gladysz K and Breborowicz J: The correlation of routine cytology with the contents of carcinoembryonic antigen and alpha-fetoprotein in pleural and peritoneal effusions. Arch Geschwulstforsch 47(3): 231-235, 1977.
7. Ghayumi SM, Mehrabi S, Doroudchi M and Ghaderi A: Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients. Pathol Oncol Res 11(4): 236-241, 2005.
8. Shitrit D, Zingerman B, Shitrit AB, Shlomi D and Kramer MR: Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 10(7): 501-507, 2005.
9. Ustun H, Borazan A, Bilgicli N and Yilmaz A: Diagnostic value of tumoural markers in pleural effusions. Int J Clin Pract 58(1): 22-25, 2004.
10. Cascinu S, Del Ferro E, Barbanti I, Ligi M, Fedeli A and Catalano G: Tumor markers in the diagnosis of malignant serous effusions. Am J Clin Oncol 20(3): 247-250, 1997.
11. European Group on Tumor Markers: Consensus Recommendations. Anticancer Res 19: 2785-2820, 1999.
12. Lejcko J, Jungerova J, Topolcan O and Koza V: Thymidine kinase at malignant lymphogranuloma and Non-Hodgkin Lymphoma. Prakt Lék 72(5): 171-173, 1992.
13. Topolcan O, Holubec L Jr, Finek J, Stieber P, Holdenrieder S, Lamerz R, Holubec Sen L, Svobodova S, Visokai V and Lipska L: Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy. Anticancer Res 25(3A): 1831-1833, 2005.
14. Alatas F, Alatas O, Metintas M, Colak O, Harmanci E and Demir S: Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 31(1): 9-16, 2001.
15. Lee JH and Chang JH: Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 128(4): 2298-2303, 2005.
16. Trape J, Molina R and Sant F: Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumour Biol 25(5-6): 276-281, 2004.
17. Dilek I, Ayakta H, Demir C, Meral C and Ozturk M: CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol 27(1): 51-55, 2005.
18. Yang Z and Xie C: Comparison of the diagnostic value of telomerase activity with CEA level in benign and malignant pleural effusions. Zhonghua Jie He He Hu Xi Za Zhi 24(4): 201-203, 2001.
19. Kuralay F, Tokgoz Z and Comlekci A: Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin. Clin Chim Acta 300(1-2): 43-55, 2000.
20. Hernandez L, Espasa A, Fernandez C, Candela A, Martin C and Romero S: CEA and CA 549 in serum and pleural fluid of patients with pleural effusion. Lung Cancer 36(1): 83-89, 2002.
21. Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vila S and Orriols R: Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 86(8): 1488-1495, 1999.
22. Paone G, De Angelis G, Greco S, Fiorucci F, Bisetti A and Ameglio F: Carcinoembryonic antigen, tissue polypeptide antigen and neuron-specific enolase pleural levels used to classify small-cell and non-small-cell lung cancer patients by discriminant analysis. J Cancer Res Clin Oncol 122(8): 499-503, 1996.
23. Toumbis M, Rasidakis A, Passalidou E, Kalomenidis J, Alchanatis M, Orphanidou D and Jordanoglou J: Evaluation of CYFRA 21-1 in malignant and benign pleural effusions. Anticancer Res 16(4A): 2101-2104, 1996.
24. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuno-de-Solo B and Estenoz-Alfaro J: Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients. Cancer 78(4): 736-740, 1996.
25. Jibiki K, Abe Y, Takeda M, Iwachika C, Odagiri E, Demura R and Demura H: Clinical evaluation of various tumor markers in pleural effusion and in the serum. Gan No Rinsho 35(9): 991-998, 1989.
26. Van Dalen A: TPS monitoring in metastatic breast cancer. Int J Biol Markers 14(1): 45-48, 1999.
27. Foresti V, Parisio E and De Filippi G: False positivity of tumor markers in pleural fluid of traumatic hemothorax. Recenti Prog Med 83(5): 295-297, 1992.
28. Molina R, Filella X, Jo J, Agusti C and Ballesta AM: CA 125 in biological fluids. Int J Biol Markers 13(4): 224-230, 1989.
29. Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, Tarakcioglu M and Buyukberber NM: Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 24(4): 172-175, 2003.
30. Sevinc A, Camci C, Turk HM and Buyukberber S: How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology 65(1): 1-6, 2003.
31. Miralles C, Orea M, Espana P, Provencio M, Sanchez A, Cantos B, Cubedo R, Carcereny E, Bonilla F and Gea T: Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 10(2): 150-154, 2003.
32. Hussain SF, Grayez J, Grigorian A and Green JT: Massive pleural effusion and marked increase of CA-125. Postgrad Med J 80(943): 300-301, 2004.
33. Topalak O, Saygili U, Soyturk M, Karaca N, Batur Y, Uslu T, Erten O. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 85(1): 108-113, 2002.